"Going Public Without an IPO: Examples from the Biotech Industry"
Event Overview: Valuations that made "sense" in 2000 have been reduced, forcing many "cram-down" financings that are painful for investors and management. Business models can and need to be as adept, flexible and creative as the science that drives our industry. There are alternative ways to "go public" that do not involve traditional capital infusion or reverse mergers and which can provide a short-term exit strategy for investors while allowing new technologies to flourish.
In this panel discussion, Rick Burgoon (V.P. Business Operations and Board member of Epiomed), Court Turner (Partner at Avalon Ventures) and Jack Florio (Sr VP Brinson Patrick Securities Corporation) will discuss pros and cons and methodologies of an innovative approach to fund-raising involving equity arrangements with development partners and the shortened S1 registration process. Div Gupta (Partner at at Latham & Watkins LLP) will moderate the discussion.
(Speaker Bios Below)
Event Location: La Jolla Woman's Club, 715 Silverado Street, La Jolla, 92037
Agenda: 6:00pm - Registration and Networking 6:45pm - Indian Dinner and Networking 7:15pm - Panel Discussion 8:30pm - Q & A Session 9:00pm - Event ends
Registration: On-line: Members: $35, Student TiE Members: $20, Non-Members: $45
On-site: Members: $40, All Students $25, Non-Members: $50
Richard P. Burgoon, Jr.is VP of Business Operations and Board Member at Epiomed Therapeutics, Inc. He co-founded GenSpera, Inc, (GNSZ.OB) a publicly-traded biopharmaceutical company. Rick previously served as President of Tulip BioMed and CEO of Aeolus Pharmaceuticals, Inc. He also served in management roles at Arena Pharmaceuticals), Cephalon, Inc. and IDEC Pharmaceuticals Corporation). Rick was twice appointed by the U.S. Secretary of Commerce to a trade advisory committee on intellectual property rights and served as Chair of the Intellectual Property Committee of the Biotechnology Industry Organization (BIO). He received his MBA from San Diego State University, and JD from the Franklin Pierce Law Center.
Court R. Turner, J.D. joined Avalon Ventures in 2008 as an Advisor and became a Venture Partner in 2010. Court is President, CEO and Director of Carolus Therapeutics, COO of Afraxis, and Director of Zacharon Pharmaceuticals, each Avalon VIII portfolio companies. Additionally, Court led Avalon's investment in RQx Pharmaceuticals as its founding CEO and Chairman; and is COO and Director of Sova Pharmaceuticals, both Avalon IX portfolio companies. Prior to Avalon Ventures he was a Vice President at Kalypsys from 2002 - 2008 and was at Aurora Biosciences from 1996 - 2002.
Jack J. Floriois Senior Vice President with Brinson Patrick Securities Corporation , a New York based investment banking boutique serving the equity capital raising needs of publicly traded companies. He is also Vice President, Marketing and Communications and an active Life Science investor with San Diego Tech Coast Angels. Previously Jack had a 30-year career with Eli Lilly and Company where he held a number of senior management positions. Since 2001, Jack has served in senior management roles in several biotech and medical device companies in the US, Europe, and China, including most recently EVP Corporate Development for Vital Therapies.
Divakar Guptais a corporate partner in Latham & Watkins' San Diego office. Div represented several public and private emerging growth and other companies, including Ambrx, Inc., ActivX Biosciences, Kyorin Pharmaceutical Co. Ltd., InterMune, Inc., and DJO Incorporated, and investment banking firms, including Jefferies & Company, Inc., Citigroup, BankofAmerica Merrill Lynch, Goldman Sachs, Piper Jaffray andOppenheimer & Co. He has handled a variety of business transactions, including public offerings of equity as well as convertible debt, venture capital financings and M&A. Recent transactions include public offerings for Ardea Biosciences, Optimer Pharmaceuticals, Somaxon Pharmaceuticals, Sequenom and Vical. Div received his BS from Yale and JD from Harvard Law School.